CryositeASX:CTE 51 14-Day RSI is 80.89 as of Jul. 11, 2026. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.95 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 218 Medical Diagnostics & Research companies, Cryosite ranks worse than 99.08% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-11), Cryosite's 14-Day RSI is 80.89.
The industry rank for Cryosite's 14-Day RSI or its related term are showing as below:
ASX:CTE's 14-Day RSI is ranked worse than 99.08% of 218
companies
in the Medical Diagnostics & Research industry
Industry Median: 49.61
vs ASX:CTE: 80.89
Cryosite (ASX:CTE) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Cryosite 14-Day RSI Related Terms
ASX:CTE vs TMO, DHR, IDXX: 14-Day RSI Comparison
For the Diagnostics & Research subindustry, Cryosite's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite 14-Day RSI vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Cryosite's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a 14-Day RSI of 80.89 as of Jul. 11, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Cryosite and its competitors. According to the industry distribution chart, Cryosite ranks #216 out of 218 companies in the Medical Diagnostics & Research industry, placing it in the top 99.1%.
Is Cryosite's 14-Day RSI too high?
Cryosite's current 14-Day RSI is 80.89. The Medical Diagnostics & Research industry median 14-Day RSI is 49.61. Cryosite's value of 80.89 is 63.1% above this industry median. Based on the distribution chart, Cryosite ranks #216 out of 218 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Cryosite has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's 14-Day RSI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #216 out of 218 companies for 14-Day RSI. This places Cryosite in the lower half of its industry. The industry median 14-Day RSI is 49.61. Cryosite's value of 80.89 is 63.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Diagnostics & Research company?
The median 14-Day RSI among Medical Diagnostics & Research companies is 49.61, based on 218 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current 14-Day RSI of 80.89 is 63.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median 14-Day RSI is 49.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current 14-Day RSI is 80.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.95, compared to a current price of A$1.25 — trading 31.6% above its estimated fair value. The current 14-Day RSI is 80.89 and 63.1% above the Medical Diagnostics & Research industry median of 49.61. Cryosite's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current 14-Day RSI is 80.89 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.25 is trading 31.6% above its estimated GF Value™ of A$0.95.
GuruFocus considers Cryosite to be Significantly Overvalued.
Key valuation signals for ASX:CTE:
14-Day RSI: 80.89
GF Value™: A$0.95 vs. price of A$1.25 (31.6% above fair value)
Industry Position: 63.1% above the Medical Diagnostics & Research median (#216 of 218)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 